Literature DB >> 12538678

Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity.

Mark P Rubinstein1, Andre N Kadima, Mohamed L Salem, Christophe L Nguyen, William E Gillanders, Michael I Nishimura, David J Cole.   

Abstract

The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeutic value in select cancer patients. This strategy is limited though, as it is often difficult, if not impossible, to obtain T cells of clinical value. The transfer of TCR genes to mature T cells to generate tumor-reactive T cells provides a potential mechanism to overcome these limitations. To evaluate the feasibility of such an approach and the quality of the resulting T cells, we generated replication-deficient retroviral vectors using the well-characterized OT-1 TCR genes. After transducing murine T cells, we were able to expand large numbers of Ag-specific T cells that were functionally active against tumor cells expressing the relevant Ag. Furthermore, we found that T cells expressing retrovirally encoded TCR had avidity that was similar to that of the parental clone. This maintenance of avidity was despite variable expression of the retrovirally encoded TCR and the presence of potentially competing endogenous TCRs. These results suggest that the inherent qualities of the TCR, as dictated by the coding sequence, are the most critical parameters in the generation of high-avidity T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538678     DOI: 10.4049/jimmunol.170.3.1209

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.

Authors:  Lisa A Jurgens; Rajiv Khanna; James Weber; Rimas J Orentas
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

2.  Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.

Authors:  Yangbing Zhao; Zhili Zheng; Paul F Robbins; Hung T Khong; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

3.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

Authors:  Cyrille J Cohen; Yangbing Zhao; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

4.  Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Authors:  Ali R Jazirehi; Stavroula Baritaki; Richard C Koya; Benjamin Bonavida; James S Economou
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Authors:  Jürgen Kuball; Michelle L Dossett; Matthias Wolfl; William Y Ho; Ralf-Holger Voss; Carla Fowler; Philip D Greenberg
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

6.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

Authors:  Marybeth S Hughes; Yik Y L Yu; Mark E Dudley; Zhili Zheng; Paul F Robbins; Yong Li; John Wunderlich; Robert G Hawley; Morvarid Moayeri; Steven A Rosenberg; Richard A Morgan
Journal:  Hum Gene Ther       Date:  2005-04       Impact factor: 5.695

7.  Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo.

Authors:  M P Rubinstein; M L Salem; A N Kadima; C L Nguyen; W E Gillanders; M I Nishimura; D J Cole
Journal:  Cancer Gene Ther       Date:  2008-08-08       Impact factor: 5.987

8.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

9.  An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.

Authors:  Niels Schaft; Miriam Coccoris; Joost Drexhage; Christiaan Knoop; I Jolanda M de Vries; Gosse J Adema; Reno Debets
Journal:  Front Immunol       Date:  2013-09-04       Impact factor: 7.561

10.  Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice.

Authors:  Julia Yuen-Shan Tsang; Yakup Tanriver; Shuiping Jiang; Shao-An Xue; Kulachelvy Ratnasothy; Daxin Chen; Hans J Stauss; R Pat Bucy; Giovanna Lombardi; Robert Lechler
Journal:  J Clin Invest       Date:  2008-10-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.